ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc. (ABOS) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B+ (3.7) | B- (3.0) | C (2.2) | D (1.5) | F (0.0) | C- (2.1) |
| 2026-11-10 | B+ (3.8) | B- (3.0) | C (2.2) | D+ (1.7) | F (0.0) | C (2.2) |
| 2026-11-03 | B+ (3.7) | B- (3.0) | C (2.3) | D+ (1.5) | F (0.0) | C- (2.1) |
| 2026-10-27 | C+ (2.5) | D+ (1.7) | C (2.4) | C+ (2.6) | C+ (2.6) | C (2.4) |
| 2026-10-20 | C+ (2.5) | C- (1.9) | C (2.4) | C (2.4) | C+ (2.6) | C (2.4) |